1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Biofrontera AG
  6. News
  7. Summary
    B8F   DE0006046113

BIOFRONTERA AG

(B8F)
  Report
Delayed Xetra  -  11:36 2022-08-16 am EDT
1.195 EUR   -0.83%
08/12Earnings Flash (BFRI) BIOFRONTERA Posts Q2 Revenue $4.5M, vs. Street Est of $4.54M
MT
08/10PTA-NEWS : Biofrontera AG: The request to convene an extraordinary shareholders' meeting by Maruho is not complied with
PU
08/05PTA-NEWS : Biofrontera AG: Maruho Deutschland GmbH demands convening of an extraordinary general meeting
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biofrontera AG Provides Earnings Guidance for the Year 2022

04/29/2022 | 05:40pm EDT

Biofrontera AG provided earnings guidance for the year 2022. The Management Board stated therein that with the expectation of a further recovery of the most important sales markets from the pandemic consequences, the company should achieve sales between EUR 24 and 27 million for the 2022 financial year following the realignment of the company through the independence of Biofrontera Inc. and deconsolidation. The company is expected to achieve approximately break-even EBITDA and a negative EBIT in the low single-digit million range in 2022.


© S&P Capital IQ 2022
All news about BIOFRONTERA AG
08/12Earnings Flash (BFRI) BIOFRONTERA Posts Q2 Revenue $4.5M, vs. Street Est of $4.54M
MT
08/10PTA-NEWS : Biofrontera AG: The request to convene an extraordinary shareholders' meeting b..
PU
08/05PTA-NEWS : Biofrontera AG: Maruho Deutschland GmbH demands convening of an extraordinary g..
PU
08/03PTA-NEWS : Biofrontera AG: Employees appeal in own statement to the shareholders not to ac..
PU
08/01Biofrontera's Management, Supervisory Boards Recommend Shareholders Reject Deutsche Bal..
MT
08/01Biofrontera Receives Australian Patent for Photodynamic Therapy to Treat Skin Diseases
MT
07/29PTA-NEWS : Biofrontera AG: Management Board and Supervisory Board jointly recommend not to..
PU
07/28PTA-DD : Biofrontera AG: Managers' transactions announcement according to article 19 MAR
PU
07/22PTA-NEWS : Biofrontera AG: Biofrontera AG will publish statement on takeover offer by Deut..
PU
07/20PTA-DD : Biofrontera AG: Managers' transactions announcement according to article 19 MAR
PU
More news
Financials
Sales 2022 35,7 M 36,3 M 36,3 M
Net income 2022 -29,0 M -29,5 M -29,5 M
Net Debt 2022 - - -
P/E ratio 2022 -2,66x
Yield 2022 -
Capitalization 67,8 M 69,0 M 69,0 M
Capi. / Sales 2022 1,90x
Capi. / Sales 2023 1,95x
Nbr of Employees 95
Free-Float 43,4%
Chart BIOFRONTERA AG
Duration : Period :
Biofrontera AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIOFRONTERA AG
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,20 €
Average target price 3,35 €
Spread / Average Target 180%
EPS Revisions
Managers and Directors
Ludwig Lutter Chief Financial Officer
Wilhelm Konrad Zours Chairman-Supervisory Board
Heikki Lanckriet Member-Supervisory Board
Helge Lubenow Member-Supervisory Board
Karlheinz Schmelig Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
BIOFRONTERA AG-19.26%70
CSL LIMITED0.87%99 406
SAMSUNG BIOLOGICS CO.,LTD.0.22%49 423
WUXI BIOLOGICS (CAYMAN) INC.-24.04%38 248
BIOGEN INC.-8.45%32 270
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-23.36%22 943